Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Amyloid-associated increases in longitudinal report of subjective cognitive complaints.

Amariglio RE, Buckley RF, Mormino EC, Marshall GA, Johnson KA, Rentz DM, Sperling RA.

Alzheimers Dement (N Y). 2018 Sep 6;4:444-449. doi: 10.1016/j.trci.2018.08.005. eCollection 2018.

2.

Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-To-Moderate Alzheimer's Disease: A Phase 2, Open Label Extension Study.

Salloway S, Marshall GA, Lu M, Brashear HR.

Curr Alzheimer Res. 2018 Aug 20. doi: 10.2174/1567205015666180821114813. [Epub ahead of print]

PMID:
30129411
3.

The Impact of Awareness of and Concern About Memory Performance on the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease Dementia.

Munro CE, Donovan NJ, Amariglio RE, Papp KV, Marshall GA, Rentz DM, Pascual-Leone A, Sperling RA, Locascio JJ, Vannini P.

Am J Geriatr Psychiatry. 2018 Aug;26(8):896-904. doi: 10.1016/j.jagp.2018.04.008. Epub 2018 May 3.

PMID:
29866588
4.

Interactive Associations of Vascular Risk and β-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study.

Rabin JS, Schultz AP, Hedden T, Viswanathan A, Marshall GA, Kilpatrick E, Klein H, Buckley RF, Yang HS, Properzi M, Rao V, Kirn DR, Papp KV, Rentz DM, Johnson KA, Sperling RA, Chhatwal JP.

JAMA Neurol. 2018 Sep 1;75(9):1124-1131. doi: 10.1001/jamaneurol.2018.1123.

PMID:
29799986
5.

PET staging of amyloidosis using striatum.

Hanseeuw BJ, Betensky RA, Mormino EC, Schultz AP, Sepulcre J, Becker JA, Jacobs HIL, Buckley RF, LaPoint MR, Vannini P, Donovan NJ, Chhatwal JP, Marshall GA, Papp KV, Amariglio RE, Rentz DM, Sperling RA, Johnson KA; Alzheimer's Disease Neuroimaging Initiative; Harvard Aging Brain Study.

Alzheimers Dement. 2018 Oct;14(10):1281-1292. doi: 10.1016/j.jalz.2018.04.011. Epub 2018 May 21.

6.

Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults.

Donovan NJ, Locascio JJ, Marshall GA, Gatchel J, Hanseeuw BJ, Rentz DM, Johnson KA, Sperling RA; Harvard Aging Brain Study.

Am J Psychiatry. 2018 Jun 1;175(6):530-537. doi: 10.1176/appi.ajp.2017.17040442. Epub 2018 Jan 12.

PMID:
29325447
7.

Advance Care Planning in Community-Dwelling Patients With Dementia.

Givens JL, Sudore RL, Marshall GA, Dufour AB, Kopits I, Mitchell SL.

J Pain Symptom Manage. 2018 Apr;55(4):1105-1112. doi: 10.1016/j.jpainsymman.2017.12.473. Epub 2017 Dec 14.

PMID:
29247754
8.

Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals.

d'Oleire Uquillas F, Jacobs HIL, Hanseeuw B, Marshall GA, Properzi M, Schultz AP, LaPoint MR, Johnson KA, Sperling RA, Vannini P.

Neuroimage Clin. 2017 Oct 31;17:388-396. doi: 10.1016/j.nicl.2017.10.034. eCollection 2018.

9.

Activities of daily living measured by the Harvard Automated Phone Task track with cognitive decline over time in non-demented elderly.

Marshall GA, Aghjayan SL, Dekhtyar M, Locascio JJ, Jethwani K, Amariglio RE, Johnson KA, Sperling RA, Rentz DM.

J Prev Alzheimers Dis. 2017;4(2):81-86. doi: 10.14283/jpad.2017.10.

10.

Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study.

Gatchel JR, Donovan NJ, Locascio JJ, Schultz AP, Becker JA, Chhatwal J, Papp KV, Amariglio RE, Rentz DM, Blacker D, Sperling RA, Johnson KA, Marshall GA.

J Alzheimers Dis. 2017;59(3):975-985. doi: 10.3233/JAD-170001.

11.

Anosognosia for memory deficits in mild cognitive impairment: Insight into the neural mechanism using functional and molecular imaging.

Vannini P, Hanseeuw B, Munro CE, Amariglio RE, Marshall GA, Rentz DM, Pascual-Leone A, Johnson KA, Sperling RA.

Neuroimage Clin. 2017 May 25;15:408-414. doi: 10.1016/j.nicl.2017.05.020. eCollection 2017.

12.

Regional 18F-Fluorodeoxyglucose Hypometabolism is Associated with Higher Apathy Scores Over Time in Early Alzheimer Disease.

Gatchel JR, Donovan NJ, Locascio JJ, Becker JA, Rentz DM, Sperling RA, Johnson KA, Marshall GA; Alzheimer's Disease Neuroimaging Initiative.

Am J Geriatr Psychiatry. 2017 Jul;25(7):683-693. doi: 10.1016/j.jagp.2016.12.017. Epub 2017 Jan 4.

13.

Hippocampal hypometabolism in older adults with memory complaints and increased amyloid burden.

Vannini P, Hanseeuw B, Munro CE, Amariglio RE, Marshall GA, Rentz DM, Pascual-Leone A, Johnson KA, Sperling RA.

Neurology. 2017 May 2;88(18):1759-1767. doi: 10.1212/WNL.0000000000003889. Epub 2017 Apr 5.

14.

Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β.

Mormino EC, Papp KV, Rentz DM, Donohue MC, Amariglio R, Quiroz YT, Chhatwal J, Marshall GA, Donovan N, Jackson J, Gatchel JR, Hanseeuw BJ, Schultz AP, Aisen PS, Johnson KA, Sperling RA.

Alzheimers Dement. 2017 Sep;13(9):1004-1012. doi: 10.1016/j.jalz.2017.01.018. Epub 2017 Feb 28.

15.

A 61-Year-Old Woman with Muscle Fatigue and Increased Cardiac Troponin.

Parsonage WA, Mikli JE, Nisbet JC, Hamilton-Craig C, Marshall GA.

Clin Chem. 2017 Jan;63(1):45-47. doi: 10.1373/clinchem.2016.254631. No abstract available.

16.

Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults.

Donovan NJ, Okereke OI, Vannini P, Amariglio RE, Rentz DM, Marshall GA, Johnson KA, Sperling RA.

JAMA Psychiatry. 2016 Dec 1;73(12):1230-1237. doi: 10.1001/jamapsychiatry.2016.2657.

17.

Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward.

Hsu D, Marshall GA.

Curr Alzheimer Res. 2017;14(4):426-440. doi: 10.2174/1567205013666160930112125. Review.

18.

Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals.

Mormino EC, Papp KV, Rentz DM, Schultz AP, LaPoint M, Amariglio R, Hanseeuw B, Marshall GA, Hedden T, Johnson KA, Sperling RA.

JAMA Neurol. 2016 Oct 1;73(10):1185-1191. doi: 10.1001/jamaneurol.2016.2237.

19.

Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly.

Chhatwal JP, Schultz AP, Marshall GA, Boot B, Gomez-Isla T, Dumurgier J, LaPoint M, Scherzer C, Roe AD, Hyman BT, Sperling RA, Johnson KA.

Neurology. 2016 Aug 30;87(9):920-6. doi: 10.1212/WNL.0000000000003050. Epub 2016 Jul 29.

20.

Elevated plasma dihydroorotate in Miller syndrome: Biochemical, diagnostic and clinical implications, and treatment with uridine.

Duley JA, Henman MG, Carpenter KH, Bamshad MJ, Marshall GA, Ooi CY, Wilcken B, Pinner JR.

Mol Genet Metab. 2016 Sep;119(1-2):83-90. doi: 10.1016/j.ymgme.2016.06.008. Epub 2016 Jun 14.

PMID:
27370710
21.

Apathy associated with neurocognitive disorders: Recent progress and future directions.

Lanctôt KL, Agüera-Ortiz L, Brodaty H, Francis PT, Geda YE, Ismail Z, Marshall GA, Mortby ME, Onyike CU, Padala PR, Politis AM, Rosenberg PB, Siegel E, Sultzer DL, Abraham EH.

Alzheimers Dement. 2017 Jan;13(1):84-100. doi: 10.1016/j.jalz.2016.05.008. Epub 2016 Jun 27. Review.

PMID:
27362291
22.

Lower Late-Life Body-Mass Index is Associated with Higher Cortical Amyloid Burden in Clinically Normal Elderly.

Hsu DC, Mormino EC, Schultz AP, Amariglio RE, Donovan NJ, Rentz DM, Johnson KA, Sperling RA, Marshall GA; Harvard Aging Brain Study.

J Alzheimers Dis. 2016 Jun 18;53(3):1097-105. doi: 10.3233/JAD-150987.

23.

Meet Our Associate Editor.

Marshall GA.

Curr Alzheimer Res. 2016;13(8):845. No abstract available.

PMID:
27291395
24.

Loneliness, depression and cognitive function in older U.S. adults.

Donovan NJ, Wu Q, Rentz DM, Sperling RA, Marshall GA, Glymour MM.

Int J Geriatr Psychiatry. 2017 May;32(5):564-573. doi: 10.1002/gps.4495. Epub 2016 May 9.

25.

High incidence of macrotroponin I with a high-sensitivity troponin I assay.

Warner JV, Marshall GA.

Clin Chem Lab Med. 2016 Nov 1;54(11):1821-1829. doi: 10.1515/cclm-2015-1276.

PMID:
27092651
26.

Maternal dementia age at onset in relation to amyloid burden in non-demented elderly offspring.

Maye JE, Betensky RA, Gidicsin CM, Locascio J, Becker JA, Pepin L, Carmasin J, Rentz DM, Marshall GA, Blacker D, Sperling RA, Johnson KA.

Neurobiol Aging. 2016 Apr;40:61-67. doi: 10.1016/j.neurobiolaging.2015.12.013. Epub 2015 Dec 28.

27.

The Harvard Automated Phone Task: new performance-based activities of daily living tests for early Alzheimer's disease.

Marshall GA, Dekhtyar M, Bruno JM, Jethwani K, Amariglio RE, Johnson KA, Sperling RA, Rentz DM.

J Prev Alzheimers Dis. 2015 Dec;2(4):242-253.

28.

Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers.

Malishkevich A, Marshall GA, Schultz AP, Sperling RA, Aharon-Peretz J, Gozes I.

J Alzheimers Dis. 2016;50(1):249-60. doi: 10.3233/JAD-150799.

29.

The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment.

Guercio BJ, Donovan NJ, Munro CE, Aghjayan SL, Wigman SE, Locascio JJ, Amariglio RE, Rentz DM, Johnson KA, Sperling RA, Marshall GA.

J Alzheimers Dis. 2015;47(2):421-32. doi: 10.3233/JAD-150146.

30.

Establishing Clinical Relevance in Preclinical Alzheimer's Disease.

Sperling RA, Amariglio RE, Marshall GA, Rentz DM.

J Prev Alzheimers Dis. 2015 Jun;2(2):85-87. No abstract available.

31.

Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers.

Gidicsin CM, Maye JE, Locascio JJ, Pepin LC, Philiossaint M, Becker JA, Younger AP, Dekhtyar M, Schultz AP, Amariglio RE, Marshall GA, Rentz DM, Hedden T, Sperling RA, Johnson KA.

Neurology. 2015 Jul 7;85(1):48-55. doi: 10.1212/WNL.0000000000001704. Epub 2015 Jun 10.

32.

Subjective cognitive concerns, amyloid-β, and neurodegeneration in clinically normal elderly.

Amariglio RE, Mormino EC, Pietras AC, Marshall GA, Vannini P, Johnson KA, Sperling RA, Rentz DM.

Neurology. 2015 Jul 7;85(1):56-62. doi: 10.1212/WNL.0000000000001712. Epub 2015 Jun 5.

33.

Functional Activities Questionnaire Items that Best Discriminate and Predict Progression from Clinically Normal to Mild Cognitive Impairment.

Marshall GA, Zoller AS, Lorius N, Amariglio RE, Locascio JJ, Johnson KA, Sperling RA, Rentz DM.

Curr Alzheimer Res. 2015;12(5):493-502.

34.

Odor identification and Alzheimer disease biomarkers in clinically normal elderly.

Growdon ME, Schultz AP, Dagley AS, Amariglio RE, Hedden T, Rentz DM, Johnson KA, Sperling RA, Albers MW, Marshall GA.

Neurology. 2015 May 26;84(21):2153-60. doi: 10.1212/WNL.0000000000001614. Epub 2015 May 1.

35.

Neuropsychiatric Symptoms and Functional Connectivity in Mild Cognitive Impairment.

Munro CE, Donovan NJ, Guercio BJ, Wigman SE, Schultz AP, Amariglio RE, Rentz DM, Johnson KA, Sperling RA, Marshall GA.

J Alzheimers Dis. 2015;46(3):727-35. doi: 10.3233/JAD-150017.

36.

Apathy is associated with lower inferior temporal cortical thickness in mild cognitive impairment and normal elderly individuals.

Guercio BJ, Donovan NJ, Ward A, Schultz A, Lorius N, Amariglio RE, Rentz DM, Johnson KA, Sperling RA, Marshall GA.

J Neuropsychiatry Clin Neurosci. 2015 Winter;27(1):e22-7. doi: 10.1176/appi.neuropsych.13060141. Epub 2014 Nov 10.

37.

Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument.

Amariglio RE, Donohue MC, Marshall GA, Rentz DM, Salmon DP, Ferris SH, Karantzoulis S, Aisen PS, Sperling RA; Alzheimer’s Disease Cooperative Study.

JAMA Neurol. 2015 Apr;72(4):446-54. doi: 10.1001/jamaneurol.2014.3375. Erratum in: JAMA Neurol. 2015 May;72(5):608.

38.

D-lactic acidosis in haematological malignancy.

Marshall GA.

Clin Chim Acta. 2015 Apr 15;444:318. doi: 10.1016/j.cca.2015.02.024. Epub 2015 Feb 20. No abstract available.

PMID:
25704297
39.

Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults.

Donovan NJ, Hsu DC, Dagley AS, Schultz AP, Amariglio RE, Mormino EC, Okereke OI, Rentz DM, Johnson KA, Sperling RA, Marshall GA.

J Alzheimers Dis. 2015;46(1):63-73. doi: 10.3233/JAD-142940.

40.

Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression.

Huijbers W, Mormino EC, Schultz AP, Wigman S, Ward AM, Larvie M, Amariglio RE, Marshall GA, Rentz DM, Johnson KA, Sperling RA.

Brain. 2015 Apr;138(Pt 4):1023-35. doi: 10.1093/brain/awv007. Epub 2015 Feb 11.

41.

Everyday cognition scale items that best discriminate between and predict progression from clinically normal to mild cognitive impairment.

Marshall GA, Zoller AS, Kelly KE, Amariglio RE, Locascio JJ, Johnson KA, Sperling RA, Rentz DM, For The Alzheimer's Disease Neuroimaging Initiative.

Curr Alzheimer Res. 2014;11(9):853-61.

42.

SIST-M-IR activities of daily living items that best discriminate clinically normal elderly from those with mild cognitive impairment.

Zoller AS, Gaal IM, Royer CA, Locascio JJ, Amariglio RE, Blacker D, Okereke OI, Johnson KA, Sperling RA, Rentz DM, Marshall GA.

Curr Alzheimer Res. 2014;11(8):785-91.

43.

Should general practitioners order troponin tests?

Marshall GA, Wijeratne NG, Thomas D.

Med J Aust. 2014 Aug 4;201(3):155-7.

PMID:
25128950
44.

Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum.

Roy K, Pepin LC, Philiossaint M, Lorius N, Becker JA, Locascio JJ, Rentz DM, Sperling RA, Johnson KA, Marshall GA.

J Alzheimers Dis. 2014;42(1):291-300. doi: 10.3233/JAD-131796.

45.

Vascular disease and risk factors are associated with cognitive decline in the alzheimer disease spectrum.

Lorius N, Locascio JJ, Rentz DM, Johnson KA, Sperling RA, Viswanathan A, Marshall GA; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimer Dis Assoc Disord. 2015 Jan-Mar;29(1):18-25. doi: 10.1097/WAD.0000000000000043.

46.

Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease.

Donovan NJ, Amariglio RE, Zoller AS, Rudel RK, Gomez-Isla T, Blacker D, Hyman BT, Locascio JJ, Johnson KA, Sperling RA, Marshall GA, Rentz DM.

Am J Geriatr Psychiatry. 2014 Dec;22(12):1642-51. doi: 10.1016/j.jagp.2014.02.007. Epub 2014 Feb 26.

47.

Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer's disease spectrum.

Marshall GA, Lorius N, Locascio JJ, Hyman BT, Rentz DM, Johnson KA, Sperling RA.

J Alzheimers Dis. 2014;41(3):719-28. doi: 10.3233/JAD-132768.

48.

Apathy is associated with increased amyloid burden in mild cognitive impairment.

Marshall GA, Donovan NJ, Lorius N, Gidicsin CM, Maye J, Pepin LC, Becker JA, Amariglio RE, Rentz DM, Sperling RA, Johnson KA.

J Neuropsychiatry Clin Neurosci. 2013 Fall;25(4):302-7. doi: 10.1176/appi.neuropsych.12060156.

49.

Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer disease spectrum.

Donovan NJ, Wadsworth LP, Lorius N, Locascio JJ, Rentz DM, Johnson KA, Sperling RA, Marshall GA; Alzheimer Disease Neuroimaging Initiative.

Am J Geriatr Psychiatry. 2014 Nov;22(11):1168-79. doi: 10.1016/j.jagp.2013.03.006. Epub 2013 Jul 24.

50.

Activities of daily living: where do they fit in the diagnosis of Alzheimer's disease?

Marshall GA, Amariglio RE, Sperling RA, Rentz DM.

Neurodegener Dis Manag. 2012 Oct 1;2(5):483-491.

Supplemental Content

Loading ...
Support Center